In contrast, in patients with NSCLC and COPD receiving preoperative neoadjuvant immunotherapy, the MPR subgroup had a higher number of MAIT cells, higher levels of GZMB and IFNγ‐R, and lower levels of PD1 IL‐17A, than the NPR subgroup (Figure 3E). This evidence concerns the gene IL17A and non-small cell lung carcinoma.